These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 26717245)

  • 21. Breaking the alliance: Defeating the tobacco industry's allies and enacting youth access restrictions in Massachusetts.
    Andersen BS; Begay ME; Lawson CB
    Am J Public Health; 2003 Nov; 93(11):1922-8. PubMed ID: 14600067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controlling corporate influence in health policy making? An assessment of the implementation of article 5.3 of the World Health Organization framework convention on tobacco control.
    Fooks GJ; Smith J; Lee K; Holden C
    Global Health; 2017 Mar; 13(1):12. PubMed ID: 28274267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Living Tomorrow Project: how Philip Morris has used a Belgian tourist attraction to promote ventilation approaches to the control of second hand smoke.
    Pilkington P; Gilmore AB
    Tob Control; 2004 Dec; 13(4):375-8. PubMed ID: 15564621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The context and quality of evidence used by tobacco interests to oppose ANVISA's 2012 regulations in Brazil.
    Lencucha R; de Lima Pontes C
    Glob Public Health; 2018 Sep; 13(9):1204-1215. PubMed ID: 28884634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. United States Food and Drug Administration's authorization of reduced exposure claims for IQOS
    Eckford R; Severini G; Sebrié EM; Muggli ME; Beem A; Rosen D; Crosbie E
    Rev Panam Salud Publica; 2022; 46():e155. PubMed ID: 36245905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tobacco industry tactics for resisting public policy on health.
    Saloojee Y; Dagli E
    Bull World Health Organ; 2000; 78(7):902-10. PubMed ID: 10994263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. "The world's most hostile environment": how the tobacco industry circumvented Singapore's advertising ban.
    Assunta M; Chapman S
    Tob Control; 2004 Dec; 13 Suppl 2(Suppl 2):ii51-7. PubMed ID: 15564221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changing conclusions on secondhand smoke in a sudden infant death syndrome review funded by the tobacco industry.
    Tong EK; England L; Glantz SA
    Pediatrics; 2005 Mar; 115(3):e356-66. PubMed ID: 15741361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Philip Morris Nordic journalist program: strategies, implementation and outcomes.
    Hiilamo H; Kahl U; Lambe M
    Health Policy; 2009 Jan; 89(1):84-96. PubMed ID: 18582983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The whole truth and nothing but the truth? The research that Philip Morris did not want you to see.
    Diethelm PA; Rielle JC; McKee M
    Lancet; 2005 Jul 2-8; 366(9479):86-92. PubMed ID: 15993237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tobacco-control policies in tobacco-growing states: where tobacco was king.
    Fallin A; Glantz SA
    Milbank Q; 2015 Jun; 93(2):319-58. PubMed ID: 26044632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tobacco industry successfully prevented tobacco control legislation in Argentina.
    Sebrié EM; Barnoya J; Pérez-Stable EJ; Glantz SA
    Tob Control; 2005 Oct; 14(5):e2. PubMed ID: 16183967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Philip Morris's website and television commercials use new language to mislead the public into believing it has changed its stance on smoking and disease.
    Friedman LC
    Tob Control; 2007 Dec; 16(6):e9. PubMed ID: 18048599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Explaining the discontinuation of a non-tobacco nicotine project at Philip Morris: obstacles to innovation.
    Cahn Z; Eckhaus L
    J Public Health Policy; 2018 May; 39(2):131-142. PubMed ID: 29531301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Who is against prevention? A map of policy actors favoring smoking in Spain].
    Granero L; Villalbí JR; Gallego R
    Gac Sanit; 2004; 18(5):374-9. PubMed ID: 15498407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The tobacco industry's worldwide ETS consultants project: European and Asian components.
    Barnoya J; Glantz SA
    Eur J Public Health; 2006 Feb; 16(1):69-77. PubMed ID: 16076855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How does the tobacco industry attempt to influence marketing regulations? A systematic review.
    Savell E; Gilmore AB; Fooks G
    PLoS One; 2014; 9(2):e87389. PubMed ID: 24505286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. "Accommodating" smoke-free policies: tobacco industry's Courtesy of Choice programme in Latin America.
    Sebrié EM; Glantz SA
    Tob Control; 2007 Oct; 16(5):e6. PubMed ID: 17897975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thinking the "unthinkable": why Philip Morris considered quitting.
    Smith EA; Malone RE
    Tob Control; 2003 Jun; 12(2):208-13. PubMed ID: 12773733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Social responsibility in tobacco production? Tobacco companies' use of green supply chains to obscure the real costs of tobacco farming.
    Otañez M; Glantz SA
    Tob Control; 2011 Nov; 20(6):403-11. PubMed ID: 21504915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.